This is a preview of subscription content, log in via an institution to check access.
Notes
Surveillance, Epidemiology, and End Results
Reference
Hassett MJ, et al. Spending for Advanced Cancer Diagnoses: Comparing Recurrent Versus De Novo Stage IV Disease. Journal of Oncology Practice : JOP1900004, 20 May 2019. Available from: URL: http://doi.org/10.1200/JOP.19.00004
Rights and permissions
About this article
Cite this article
US spending for advanced cancer: de novo vs recurrent disease. PharmacoEcon Outcomes News 829, 34 (2019). https://doi.org/10.1007/s40274-019-5948-9
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-019-5948-9